Inventor
Tony P. Tang
Inventor
Boulder, CO, US
Overview
Patents· 28 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Dprimary
C07DHeterocyclic compounds31%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations30%
A61KPreparations for medical, dental or toiletry purposes23%
C07CAcyclic or carbocyclic compounds5%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms3%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium2%
G01NInvestigating or analysing materials by determining their chemical or physical properties2%
H05KPrinted circuits2%
C07BGeneral methods of organic chemistry1%
PatentTitleYear
10,766,8812-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases202010,745,419Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile202010,730,8804,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors202010,647,715KRas G12C inhibitors202010,633,381KRas G12C inhibitors202010,584,124Crystalline forms202010,555,944Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors202010,441,581Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors201910,208,0242-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases201910,189,8454,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors201910,172,845Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors201910,172,851Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors201910,154,995Serine/threonine kinase inhibitors201810,144,734Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors201810,137,124Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors201810,125,134KRas G12C inhibitors201810,112,942Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors20189,763,942'Serine/threonine kinase inhibitors'20179,346,805'Pyrimidyl cyclopentanes as Akt protein kinase inhibitors'20169,328,091'5H-cyclopenta[d]pyrimidines as AKT protein kinase inhibitors'20168,895,566'5H-cyclopenta[d]pyrimidines as AKT protein kinase inhibitors'20148,329,709'5H-cyclopenta[D]pyrimidines as AKT protein kinase inhibitors'20128,324,221'Pyrimidyl cyclopentanes as Akt protein kinase inhibitors'20127,858,646'Potentiators of glutamate receptors'20107,816,523'Potentiators of glutamate receptors'20107,803,938'Potentiators of glutamate receptors'20107,678,794'Potentiators of glutamate receptors'20107,598,423'Potentiators of glutamate receptors'2009Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2009–2020Patents assigned to LILLY CO ELI (6)· patent assignee history
2009–2010Based in Longmont, CO, US· patent location history
2012–2020Patents assigned to ARRAY BIOPHARMA INC (23)· patent assignee history
2012–2018Patents assigned to GENENTECH INC (5)· patent assignee history
2012Patents assigned to BANKA ANNA L (2)· patent assignee history
2012–2020Based in Boulder, CO, US· patent location history
2018–2020Patents assigned to MIRATI THERAPEUTICS INC (3)· patent assignee history
2018Based in Boudler, CO, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| ARRAY BIOPHARMA INC | 23 | 2012–2020 |
| LILLY CO ELI | 6 | 2009–2020 |
| GENENTECH INC | 5 | 2012–2018 |
| MIRATI THERAPEUTICS INC | 3 | 2018–2020 |
| BANKA ANNA L | 2 | 2012 |
Locations
| Location | Patents | Span |
|---|---|---|
| Boulder, CO, US | 22 | 2012–2020 |
| Longmont, CO, US | 5 | 2009–2010 |
| Boudler, CO, US | 1 | 2018 |